Approach to Indeterminate Beta-D-Glucan Results
Understanding Indeterminate Results
- The Infectious Diseases Society of America recommends that an indeterminate beta-D-glucan result should prompt repeat testing within 3-5 days combined with comprehensive clinical assessment for invasive fungal infection risk factors, rather than triggering immediate antifungal therapy, as single positive results have poor specificity and consecutive positive results significantly improve diagnostic accuracy 1, 2
- Beta-D-glucan testing has significant limitations with false positivity being a major concern, particularly when common confounding factors are present 1, 2
- The specificity of beta-D-glucan can be improved by requiring consecutive positive results rather than relying on a single result 1, 2, 3
Immediate Assessment Steps
Identify Confounding Factors for False Positives
- Evaluate for the following causes of false positive results: gram-positive or gram-negative bacteremia 1, 2, 3
- Hemodialysis is a cause of false positive results 1, 4
- Receipt of albumin or intravenous immunoglobulin products can cause false positive results 1, 4
- Certain antibiotics, particularly intravenous amoxicillin-clavulanate or piperacillin-tazobactam, can cause false positive results 1, 4
- Exposure to surgical gauze or other materials containing glucan can cause false positive results 1, 4
- Mucositis or gastrointestinal mucosal disruption can cause false positive results 1, 2
- Fungal colonization without invasive disease can cause false positive results 1
Assess Clinical Risk Factors for Invasive Fungal Infection
- Neutropenia or hematologic malignancy are risk factors for invasive fungal infection 4, 5, 6
- Hematopoietic stem cell or solid organ transplantation are risk factors for invasive fungal infection 6
- Prolonged ICU stay with multiple risk factors is a risk factor for invasive fungal infection 6
- Recent abdominal surgery with complications is a risk factor for invasive fungal infection 5
- Clinical signs of infection including persistent fever despite antibiotics are risk factors for invasive fungal infection 1, 5
Diagnostic Algorithm
Step 1: Repeat Beta-D-Glucan Testing
- Obtain a second beta-D-glucan test within 3-5 days to determine if results are consistently positive 1, 2, 3
- Two consecutive positive results significantly improve specificity compared to a single positive test 1, 2
Step 2: Obtain Complementary Diagnostic Tests
- Blood cultures (at least two sets from different sites) should be obtained 5, 6, 7
- Serum galactomannan testing should be performed if aspergillosis is suspected 4, 6
- High-resolution chest CT should be performed if pulmonary involvement is suspected 4, 6
- Site-specific cultures from normally sterile sites should be obtained when clinically indicated 5, 6, 7
Special Populations and Considerations
Pediatric Patients
- Beta-D-glucan testing is not currently recommended to guide pediatric clinical decision-making 1, 2, 8
- Mean beta-D-glucan levels are slightly higher in uninfected children compared to adults, and optimal thresholds for positivity are not established 1, 2, 8
Lung Transplant Recipients
- Beta-D-glucan has particularly poor performance in lung transplant recipients, with specificity as low as 9% and positive predictive value of only 14% 1, 2
- In one study, 90% of lung transplant patients had at least one positive result, making routine surveillance testing unreliable in this population 1, 2
Patients on Antifungal Prophylaxis
- Sensitivity of beta-D-glucan may be reduced in patients receiving mold-active antifungal prophylaxis 4
- False negative results can occur with concomitant use of anti-mold antifungal agents 4
Important Caveats and Pitfalls
Test Limitations
- Beta-D-glucan does NOT detect mucormycosis (zygomycetes) or most Cryptococcus species 9
- If mucormycosis is suspected based on negative galactomannan and clinical presentation, beta-D-glucan negativity increases the likelihood of this diagnosis 9
- The test detects Candida, Aspergillus, Pneumocystis, and Fusarium species but cannot differentiate between them 4
Avoid Common Errors
- Do not initiate antifungal therapy based solely on a single indeterminate beta-D-glucan result without supporting clinical or microbiological evidence 5, 6
- Do not use beta-D-glucan results from respiratory secretions or colonization sites to guide treatment decisions 5
- Do not ignore the high negative predictive value (>90%): a negative result is useful for ruling out invasive fungal infection 6
When to Consider Empiric Antifungal Therapy
- Start empiric therapy while awaiting repeat testing if the patient is critically ill with septic shock and high clinical suspicion for invasive candidiasis 7
- Start empiric therapy while awaiting repeat testing if the patient is neutropenic with persistent fever despite broad-spectrum antibiotics and high-risk features 4, 5
- Start empiric therapy while awaiting repeat testing if there is clinical deterioration with radiographic findings suggestive of invasive fungal infection 4, 6
- The preferred empiric regimen for suspected invasive candidiasis is an echinocandin (caspofungin 70 mg loading, then 50 mg daily; micafungin 100 mg daily; or anidulafungin 200 mg loading, then 100 mg daily) 1, 8, 7
Cefepime and False-Positive Beta-D-Glucan Results
Evidence for Cefepime-Associated False Positives
- The German Society of Hematology and Medical Oncology guidelines explicitly identify cefepime as one of several semisynthetic β-lactam antibiotics that can produce false-positive results on both galactomannan and beta-D-glucan testing, alongside other β-lactams including Amoxicillin-clavulanate, Piperacillin-tazobactam, Carbapenems, and Ceftriaxone 10, 11
- Cefepime can cause false-positive beta-D-glucan test results, which should be considered when interpreting elevated levels in patients receiving this antibiotic 10, 11